The role of insulin-like growth factor IGF-I in inflammation mechanisms in ulcerative colitis


DOI: https://dx.doi.org/10.18565/therapy.2019.3.67-71

Pavlenko V.V., Alferov V.V., Pavlenko A.F.

Department of propaedeutics of internal diseases of Stavropol State medical University of the Ministry of Healthcare of Russia
The purpose is to define the role of IGF-I in the mechanisms of large intestine inflammation with an ulcerative colitis (UC).
Material and methods. Surveyed 35 patients with varying severity of UC in the dynamics of treatment. Determination of insulin-like growth factor IGF-I in peripheral blood and cytokine TNF-a in mononuclear cells was performed by ELISA. The cellular composition of the inflammatory infiltrate of the mucosal lamina propria was studied.
Results and conclusion. It was found that during the exacerbation of ulcerative colitis, the IGF-I content in peripheral blood was reduced, and TNF-α synthesis was increased. The content of IGF-I in the serum of patients was inversely dependent on the severity of UC, the degree of inflammatory reaction in the SOT and the production of TNF-α by mononuclears. The formation of clinical remission of UC was accompanied by an increase in the production of IGF-I and a decrease in the synthesis of TNF-α.
Keywords: insulin-like growth factor, ulcerative colitis, cytokines
Read entire article

Literature


  1. Hart A.L., Lomer M., Verjee A., Kemp K., Faiz O., Daly A., Solomon J., McLaughlin J. What are the Top 10 research questions in the treatment of inflammatory bowel disease? Journal of Crohn’s and Colitis. 2017; 7: 204–11.

  2. Fakhoury M., Negrulj R., Mooranian A. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 21: 113–20.

  3. Sanderson I.R. Growth problems in children with IBD. Nat Rev Gastroenterol. Hepatol. 2014; 11(10): 601–10.

  4. Zatorski H., Marynowski M., Fichna J. Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy. Pharmacol Rep. 2016 Aug; 68(4): 809–15. http://dx.doi.org/10.1016/j.pharep, 2016.03.006.

  5. Falvey J.D., Hoskin T., Meijer B. Disease activity assessment in IBD: Clinical indices and biomarkers fail to predict endoscopic remission. Inflamm. Bowel Dis. 2015; 21: 824–31.

  6. Theiss A.L., Fruchtman S., Lund P.K. Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm. Bowel Dis. 2004; 10(6): 871–80.

  7. Thayu M., Denson L.A., Shults J., Zemel B.S., Burnham J.M., Baldassano R.N. Determinants of changes in linear growth and body composition in incident pediatric Crohn’s disease. J. Gastroenterol. 2010; 139(2): 430–38.

  8. Li P., Liang M.L., Zhu Y.., Gong Y.Y., Wang Y., Heng D. Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts. World J. Gastroenterol. 2014; 20(16): 4648–61.

  9. Sanderson I.R. Growth problems in children with IBD. Nat. Rev. Gastroenterol Hepatol. 2014; 11(10): 601–10.

  10. Eivindson M., Nielsen J.N., Gronbaek H., Flyvbjerg A., Hey H. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. Horm. Res. 2011; 64(1): 9–15.

  11. Underwood L.E. Growth hormone treatment, acromegaly, and relationship to cancer and leukemia. In Bercu BB & Walker RF (eds) Growth Hormone II: Basic and Clinical Aspects, New York: Springer Verlag: 2010; 259–68.

  12. Emmerson E., Campbell L., Davies F.C.J., Ross N.L., Ashcroft G.S., Krust A. Insulin-like growth factor-1 promotes wound healing in estrogen-deprived mice: new insights into cutaneous IGF-1R/ER[alpha] cross talk. J. Investig. Dermatol. 2012; 132(12): 2838–48.

  13. Lee K.W., Ma L., Yan X., Liu B., Zhang X.K., Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J. Biol. Chem. 2009; 280(17): 16942–48.

  14. Tyler J.A. Insulin-like growth factor I can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. J. of Biochem. 2012; 260: 543–48.

  15. Steven J.B., Lloyd M. The Immune Response in Inflammatory Bowel Disease. Am. J. Gastroenterol. 2007; 102: 2058–69.


About the Autors

Vladimir V. Pavlenko, MD, professor, the Head Department of propaedeutics of internal diseases of Stavropol State medical University of the Ministry of Healthcare of Russia. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (903) 445-17-48. E-mail: PavlenkoVV@yandex.ru
Vladimir V. Alferov, PhD., assistant of the Department of propaedeutics of internal diseases of Stavropol State medical University of the Ministry of Healthcare of Russia. Address: 355017, Stavropol, 310 Mira str. Tel.: +7 (928) 012-44-49. E-mail: E-mail: v.v.alferov@mail.ru
Alla F. Pavlenko, PhD, associate professor of the Department of therapy with the course of dietetics of Stavropol State medical University of the Ministry of Healthcare of Russia. Address: 355017, Stavropol, 310 Mira str.
Tel.: +7 (903) 445-17-47. E-mail: Pavlenkoa.f@yandex.ru


Similar Articles

Back to Content

Бионика Медиа